ATE79649T1 - Herpes simplex-virus als vektor. - Google Patents

Herpes simplex-virus als vektor.

Info

Publication number
ATE79649T1
ATE79649T1 AT85303791T AT85303791T ATE79649T1 AT E79649 T1 ATE79649 T1 AT E79649T1 AT 85303791 T AT85303791 T AT 85303791T AT 85303791 T AT85303791 T AT 85303791T AT E79649 T1 ATE79649 T1 AT E79649T1
Authority
AT
Austria
Prior art keywords
vector
herpes simplex
simplex virus
foreign gene
expression
Prior art date
Application number
AT85303791T
Other languages
English (en)
Inventor
Bernard Roizman
Original Assignee
Pasteur Merieux Serums Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc
Application granted granted Critical
Publication of ATE79649T1 publication Critical patent/ATE79649T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT85303791T 1984-06-04 1985-05-30 Herpes simplex-virus als vektor. ATE79649T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61693084A 1984-06-04 1984-06-04
EP85303791A EP0176170B1 (de) 1984-06-04 1985-05-30 Herpes simplex-Virus als Vektor

Publications (1)

Publication Number Publication Date
ATE79649T1 true ATE79649T1 (de) 1992-09-15

Family

ID=24471577

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85303791T ATE79649T1 (de) 1984-06-04 1985-05-30 Herpes simplex-virus als vektor.

Country Status (6)

Country Link
US (3) US5599691A (de)
EP (1) EP0176170B1 (de)
JP (2) JP2664892B2 (de)
AT (1) ATE79649T1 (de)
CA (1) CA1282721C (de)
DE (1) DE3586520T2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5763269A (en) * 1985-09-06 1998-06-09 Syntro Corporation Recombinant infectious bovine rhinotrocheitis virus
SE8505027D0 (sv) * 1985-10-24 1985-10-24 Kabigen Ab A lytic virulent phage, a hostcell containing same and a process for protein production
AU623333B2 (en) * 1986-01-27 1992-05-14 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
NZ220645A (en) * 1986-06-20 1989-10-27 Merck & Co Inc Modified varicella-zoster virus and its cultivation
FR2601689B1 (fr) * 1986-07-17 1992-10-16 Syntro Corp Herpes virus attenues, herpes virus qui renferment de l'adn etranger codant pour une sequence d'amino-acides, et vaccins les contenant
AU612983B2 (en) * 1986-08-01 1991-07-25 Australian National University, The Recombinant vaccine
US5866136A (en) * 1986-08-01 1999-02-02 Commonwealth Scientific And Industrial Organisation Recombinant vaccine
FR2602790B1 (fr) * 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
EP0277773A1 (de) * 1987-01-30 1988-08-10 The Board Of Trustees Of The Leland Stanford Junior University Mischcytomegalovirus und Vakzin
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
EP0326127A3 (de) * 1988-01-26 1990-03-28 Novagene, Inc. Infektiöse Rinder-Rhinotracheitis-Virus-Insertionsmutanten, sie enthaltende Impfstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung
GB8918616D0 (en) * 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5849572A (en) * 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
EP0675962B1 (de) * 1992-12-23 2003-02-05 Arch Development Corporation Synthetische promotoren von herpes simplex virus
WO1994020517A1 (en) * 1993-03-08 1994-09-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for treating a connective tissue of a mammalian host
WO1996038546A1 (en) * 1995-06-01 1996-12-05 Merck & Co., Inc. Herpes simplex type 1 protease mutants and vectors
US6344445B1 (en) 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
ATE446368T1 (de) 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
US6783972B1 (en) 1998-09-22 2004-08-31 University Of Florida Research Foundation Methods for large-scale production of recombinant AAV vectors
US6774119B1 (en) 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6764675B1 (en) * 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
EP1170363B1 (de) * 2000-02-02 2007-11-21 Kaneda, Yasufumi VIRUS-HüLLENVEKTOR FüR GENTRANSFER
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
US7060442B2 (en) * 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
EP1356071B1 (de) 2000-11-28 2007-11-21 The University of Chicago Genetisch veränderter herpes virus für die behandlung von herz- und gefässerkrankungen
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
EP1549339B1 (de) * 2002-10-07 2019-06-05 University Of Chicago Targeting von herpes simplex virus an spezifische rezeptoren
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
US7550148B2 (en) * 2002-10-07 2009-06-23 The University Of Chicago Targeting of Herpes simplex virus to specific receptors
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
KR101222281B1 (ko) 2004-03-29 2013-01-28 가르파마 컴퍼니 리미티드 신규 갈렉틴 9 개변체 단백질 및 그 용도
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20080089910A1 (en) * 2004-06-29 2008-04-17 Visalli Et Al Attenuated Herpes Simplex Virus Type-2, Vectors Thereof and Immunogenic Compositions Thereof
EP2551282A3 (de) 2005-03-23 2013-02-13 Genmab A/S Antikörper gegen CD38 zur Behandling von multiplem Myelom
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
CA2703263C (en) 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
NO2700405T3 (de) 2008-05-29 2018-09-01
EP3400291B2 (de) 2016-01-08 2024-02-28 Replimune Limited Manipulierter virus
US10350542B2 (en) 2016-04-29 2019-07-16 General Electric Company Wet flue gas desulfurization system with zero waste water liquid discharge
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN118252954A (zh) 2017-07-13 2024-06-28 迈阿密大学 用于管理疼痛的方法
CN112601547A (zh) 2018-06-21 2021-04-02 雷普利穆内有限公司 使用溶瘤病毒的治疗
ES3055327T3 (en) 2021-08-06 2026-02-11 Nabrawind Tech S L Transition for composite laminates for a modular blade

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0074808A3 (de) 1981-09-16 1984-07-04 University Patents, Inc. Rekombinantes Verfahren und Materialien
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
AU570940B2 (en) * 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US5288641A (en) * 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector

Also Published As

Publication number Publication date
US5599691A (en) 1997-02-04
EP0176170A1 (de) 1986-04-02
EP0176170B1 (de) 1992-08-19
JP2664892B2 (ja) 1997-10-22
DE3586520T2 (de) 1993-01-07
JPH06181780A (ja) 1994-07-05
US6071692A (en) 2000-06-06
JPS611390A (ja) 1986-01-07
US5846707A (en) 1998-12-08
DE3586520D1 (de) 1992-09-24
JP2641688B2 (ja) 1997-08-20
CA1282721C (en) 1991-04-09

Similar Documents

Publication Publication Date Title
DE3586520D1 (de) Herpes simplex-virus als vektor.
DK0738327T3 (da) Vært-vektorsystem til anvendelse ved genterapi
ATE130870T1 (de) Von adeno-assoziierte viren rekombinante vektoren.
PL333070A1 (en) Infectious clones of rna viruses and vaccines based on them
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
HUT72987A (en) Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
BG60107B2 (bg) Метод за получаване на еукариотен полипептид
DK0425004T3 (de)
IL87041A0 (en) Induction of virus resistance in plants,recombinant dna molecules for use therein,their preparation and vectors and host cells comprising them
DK1021553T3 (da) Eukaryotisk genekspressionskassette og anvendelser deraf
PT632129E (pt) Vectores recombinantes de virus sincicial para utilizacoes medicinais e de diagnostico e processos para a preparacao de vectores recombinantes de virus sincicial
DK0566554T3 (da) Fremstilling af rekombinante proteiner ved anvendelse af herpesviruspromotorer og VP16-transaktivatorer
EP0216564A3 (de) Infektiöses rekombinantes Virus, dieses enthaltende Impfstoffe gegen feline Leukämie und Verfahren zu deren Herstellung
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
EP0326127A3 (de) Infektiöse Rinder-Rhinotracheitis-Virus-Insertionsmutanten, sie enthaltende Impfstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung
IL88371A0 (en) Directed integration of genes into a plant genome and recombinant dna,expression vectors and host cells used therefor
DK498387D0 (da) Virus-dna-sekvens
EP0164245A3 (de) NIF-Promotor von Rhizobium japonicum
DK0478696T3 (da) Effektiv fremgangsmåde til identificerbar udtrykkelse af ikke-selekterbare gener
EP0260090A3 (de) Expression von Hepatitis B-Virusantigenen von rekombinanten Bakulovirusvektoren
EP0276591A3 (en) Viral vector and recombinant dna coding for the p25 protein of the aids virus
SU1380209A1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК PUR 291-HAV 22, КОДИРУЮЩАЯ СИНТЕЗ ГИБРИДНОГО ПОЛИПЕПТИДА АНТИГЕННЫХ ДЕТЕРМИНАНТ ВИРУСА ГЕПАТИТА А С β -ГАЛАКТОЗИДАЗОЙ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time